Heteroclitic immunization induces tumor immunity Journal Article


Authors: Dyall, R.; Bowne, W. B.; Weber, L. W.; LeMaoult, J.; Szabo, P.; Moroi, Y.; Piskun, G.; Lewis, J. J.; Houghton, A. N.; Nikolić-Žugić, J.
Article Title: Heteroclitic immunization induces tumor immunity
Abstract: In tumor transplantation models in mice, cytotoxic T lymphocytes (CTLs) are typically the primary effector cells. CTLs recognize major histocompatibility complex (MHC) class I-associated peptides expressed by tumors, leading to tumor rejection. Peptides presented by cancer cells can originate from viral proteins, normal self-proteins regulated during differentiation, or altered proteins derived from genetic alterations. However, many tumor peptides recognized by CTLs are poor immunogens, unable to induce activation and differentiation of effector CTLs. We used MHC binding motifs and the knowledge of class I:peptide:TCR structure to design heteroclitic CTL vaccines that exploit the expression of poorly immunogenic tumor peptides. The in vivo potency of this approach was demonstrated using viral and self-(differentiation) antigens as models. First, a synthetic variant of a viral antigen was expressed as a tumor antigen, and heteroclitic immunization with peptides and DNA was used to protect against tumor challenge and elicit regression of 3-d tumors. Second, a peptide from a relevant self-antigen of the tyrosinase family expressed by melanoma cells was used to design a heteroclitic peptide vaccine that successfully induced tumor protection. These results establish the in vivo applicability of heteroclitic immunization against tumors, including immunity to poorly immunogenic self-proteins.
Keywords: nonhuman; animal cell; cancer immunotherapy; melanoma; animal model; tumors; antigen recognition; vaccination; cytotoxic t lymphocyte; lymphoma; tumor cell; major histocompatibility complex; major histocompatibility antigen class 1; immunization; peptide vaccines; major histocompatibility complex class i; female; priority journal; article; heteroclitic peptides
Journal Title: Journal of Experimental Medicine
Volume: 188
Issue: 9
ISSN: 0022-1007
Publisher: Rockefeller University Press  
Date Published: 1998-11-02
Start Page: 1553
End Page: 1561
Language: English
DOI: 10.1084/jem.188.9.1553
PUBMED: 9802967
PROVIDER: scopus
PMCID: PMC2212523
DOI/URL:
Notes: Article -- Export Date: 12 December 2016 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jonathan J Lewis
    109 Lewis
  2. Rubendra Dyall
    33 Dyall
  3. Yoichi Moroi
    15 Moroi
  4. Wilbur B Bowne
    20 Bowne
  5. Alan N Houghton
    364 Houghton